Human FGFR3 Extracellular Domain (Recombinant) – Research Use Only

The Human FGFR3 Extracellular Domain (recombinant) is a biotechnology‑grade preparation of the soluble extracellular region of Fibroblast Growth Factor Receptor 3 (FGFR3). FGFR3 is a receptor tyrosine kinase involved in cell growth, differentiation, and developmental signaling. The extracellular domain mediates ligand binding and receptor dimerization, making it a valuable tool for studying FGFR3–ligand interactions, receptor activation mechanisms, and structure–function relationships. This recombinant protein is suitable for biochemical assays, binding studies, protein interaction analysis, and receptor biology research.

Scientific Overview

FGFR3 is a member of the fibroblast growth factor receptor family and plays essential roles in skeletal development, cellular signaling, and receptor tyrosine kinase regulation. The extracellular domain (ECD) contains immunoglobulin‑like domains responsible for ligand recognition and receptor dimerization. Recombinant FGFR3 ECD is widely used to study ligand binding, receptor activation, structural biology, and interactions with regulatory proteins or antibodies. This soluble form enables in vitro characterization of FGFR3 signaling mechanisms without the complexity of full‑length membrane‑bound receptor systems.

Common Research Applications

• FGF–FGFR binding and affinity studies
• Receptor–ligand interaction assays
• Structural and biophysical analysis of FGFR3 ECD
• Protein–protein interaction mapping
• Antibody development and epitope characterization
• Receptor biology and tyrosine kinase signaling research

Usage & Handling Guidance

Store at -80 °C. Thaw on ice and aliquot immediately to avoid freeze–thaw cycles. Use low‑binding tubes for protein handling. For binding assays or structural studies, maintain samples at 4 °C during experimental setup and avoid extended exposure to room temperature.

• Storage: -80 °C
• Handling: Aliquot upon receipt; avoid freeze–thaw cycles
• Compatibility: Biochemical assays, binding studies, structural biology

What You Get

• 50 µg recombinant Human FGFR3 Extracellular Domain
• Ready‑to‑use solution for biochemical and receptor‑binding workflows
• Batch‑specific documentation available upon request
• For research use only (RUO)

Frequently Asked Questions

• What region of FGFR3 does this protein include?
  This product contains the soluble extracellular domain (ECD) of FGFR3, which includes the ligand‑binding immunoglobulin‑like domains.
• Is this protein suitable for ligand‑binding assays?
  Yes. The FGFR3 ECD is commonly used for in vitro binding, affinity, and interaction studies.
• Can this protein be used for antibody development?
  Yes. The ECD is frequently used for generating and characterizing antibodies targeting FGFR3.
• Does this product contain the transmembrane or kinase domains?
  No. This preparation includes only the extracellular domain.
• How should the protein be stored?
  Store at -80 °C and avoid repeated freeze–thaw cycles.
• Is this product suitable for diagnostic or therapeutic use?
  No. This reagent is intended strictly for in vitro research use only (RUO).

---

References

• Klag KA, Horton WA. Advances in treatment of achondroplasia and osteoarthritis Hum Mol Genet. 2016 Apr 15;25(R1):R2-8.
• Martínez-Torrecuadrada J, Cifuentes G, López-Serra P, Saenz P, Martínez A, Casal JI. Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation Clin Cancer Res. 2005 Sep 1;11(17):6280-90.
• Gorbenko O, Ovcharenko G, Klymenko T, Zhyvoloup O, Gaman N, Volkova D, Gout I, Filonenko V. Generation of monoclonal antibody targeting fibroblast growth factor receptor 3 Hybridoma (Larchmt). 2009 Aug;28(4):295-300.
• Keegan K, Johnson DE, Williams LT, Hayman MJ. Isolation of an additional member of the fibroblast growth factor receptor family, FGFR-3 Proc Natl Acad Sci U S A. 1991 Feb 15;88(4):1095-9.
• McKie AB, Vaughan S, Zanini E, Okon IS, Louis L, de Sousa C, Greene MI, Wang Q, Agarwal R, Shaposhnikov D, Wong JL, Gungor H, Janczar S, El-Bahrawy M, Lam EW, Chayen NE, Gabra H. The OPCML tumor suppressor functions as a cell surface repressor-adaptor, negatively regulating receptor tyrosine kinases in epithelial ovarian cancer Cancer Discov. 2012 Feb;2(2):156-71.
• Webster MK, Donoghue DJ. Enhanced signaling and morphological transformation by a membrane-localized derivative of the fibroblast growth factor receptor 3 kinase domain Mol Cell Biol. 1997 Oct;17(10):5739-47.
• Gorbenko O, Ovcharenko G, Volkova D, Mayilo D, Gaman N, Khozhayenko Y, Usenko V, Gout I, Filonenko V. Monoclonal antibodies with selective specificity towards different glycosylation isoforms of FGFR1 Hybridoma (Larchmt). 2009 Aug;28(4):287-93.
• Naski MC, Wang Q, Xu J, Ornitz DM. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia Nat Genet. 1996 Jun;13(2):233-7.
• Galvin BD, Hart KC, Meyer AN, Webster MK, Donoghue DJ. Constitutive receptor activation by Crouzon syndrome mutations in fibroblast growth factor receptor (FGFR)2 and FGFR2/Neu chimeras Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7894-9.